| __timestamp | ADMA Biologics, Inc. | Amphastar Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9517014 | 28427000 |
| Thursday, January 1, 2015 | 7015946 | 37065000 |
| Friday, January 1, 2016 | 7688238 | 41199000 |
| Sunday, January 1, 2017 | 6229587 | 43415000 |
| Monday, January 1, 2018 | 3926120 | 57564000 |
| Tuesday, January 1, 2019 | 2343848 | 68853000 |
| Wednesday, January 1, 2020 | 5907013 | 67229000 |
| Friday, January 1, 2021 | 3646060 | 60932000 |
| Saturday, January 1, 2022 | 3613764 | 74771000 |
| Sunday, January 1, 2023 | 3300000 | 73741000 |
Data in motion
In the competitive landscape of biopharmaceuticals, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, ADMA Biologics, Inc. and Amphastar Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments.
From 2014 to 2023, ADMA Biologics, Inc. has seen a fluctuating R&D budget, peaking in 2014 with approximately $9.5 million. However, by 2023, their investment had decreased by about 65%, reflecting a strategic shift or potential financial constraints.
Conversely, Amphastar Pharmaceuticals, Inc. has consistently increased its R&D spending, growing from $28 million in 2014 to over $74 million in 2023. This represents a 165% increase, underscoring their commitment to innovation and expansion in the pharmaceutical market.
These trends highlight the diverse approaches companies take in navigating the dynamic biopharma industry.
Comparing Innovation Spending: Merck & Co., Inc. and ADMA Biologics, Inc.
Comparing Innovation Spending: Incyte Corporation and Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and ADMA Biologics, Inc.
Comparing Innovation Spending: Sarepta Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Analyzing R&D Budgets: Opthea Limited vs Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for ADMA Biologics, Inc. and Iovance Biotherapeutics, Inc.
Research and Development: Comparing Key Metrics for ADMA Biologics, Inc. and Viridian Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. or MannKind Corporation: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Amphastar Pharmaceuticals, Inc. and Celldex Therapeutics, Inc.
R&D Insights: How Amphastar Pharmaceuticals, Inc. and Viridian Therapeutics, Inc. Allocate Funds